Filing Flows › Caris Life Sciences (CAI) › R&D spending
Caris Life Sciences (CAI) R&D spending by quarter
Caris Life Sciences' R&D spending was $33.8M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 6 quarters it ranged from $21.6M (Q3 2025) to $33.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $33.8M | +5% | +56% |
| Q2 2026 | $32.4M | +3% | +29% |
| Q1 2026 | $31.3M | -2% | — |
| Q4 2025 | $31.8M | +47% | — |
| Q3 2025 | $21.6M | -14% | — |
| Q2 2025 | $25.0M | — | — |
Q3 2026 at a glance
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Caris Life Sciences' R&D spending?
Caris Life Sciences' R&D spending was $33.8M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Caris Life Sciences' R&D spending changed?
Over the last 6 quarters it ranged from $21.6M (Q3 2025) to $33.8M (Q3 2026).